Callan Family Office’s Gilead Sciences GILD Stock Holding History

Callan Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.5M	Sell	103,771 -2,099	-2%	-$294K	0.33%	60
2025 Q4	$13M	Buy	105,870 +17,592	+20%	+$2.14M	0.28%	69
2025 Q3	$9.8M	Sell	88,278 -1,460	-2%	-$166K	0.31%	62
2025 Q2	$9.95M	Buy	89,738 +63,300	+239%	+$6.74M	0.31%	60
2025 Q1	$2.96M	Sell	26,438 -4,149	-14%	-$428K	0.22%	100
2024 Q4	$2.83M	Buy	+30,587	New	+$2.75M	0.18%	113
2023 Q2	–	Sell	-13,778	Closed	-$1.14M	–	131
2023 Q1	$1.14M	Buy	+13,778	New	+$1.14M	0.28%	54

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Callan Family Office's GILD Position: Q1 2026 in Review

Callan Family Office reduced its Gilead Sciences (GILD) stake by 2% in Q1 2026, selling an estimated $294K and leaving 103,771 shares worth $14.5M. The position accounts for 0.33% of the portfolio, ranked #60.

Callan Family Office first reported a position in GILD in Q1 2023 and has held it in 7 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Callan Family Office held 103,771 shares of Gilead Sciences worth $14.5M as of Q1 2026.
Callan Family Office sold 2,099 Gilead Sciences shares in Q1 2026, an estimated $294K.
Gilead Sciences made up 0.33% of Callan Family Office's portfolio in Q1 2026, its #60 holding.
Callan Family Office first reported a position in Gilead Sciences in Q1 2023 and has held it in 7 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.